Feed CYTK
CY

Cytokinetics CYTK · NASDAQ

$62.65 +1.13% (+$0.70)

Market cap
$8.71B
Enterprise value
$9.73B
P/E
-
Forward P/E
-
PEG
-
P/S
122.7x
P/FCF
-
EV/EBITDA
-
ROIC
-39.3%
Gross margin
85.0%
Net margin
-1,259.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.36
Free float
96.5%

About the company

Cytokinetics, Incorporated is an American biotechnology company specializing in the development of therapeutic approaches aimed at improving muscle function in patients with heart and muscle diseases. The company develops innovative drug candidates targeting the regulation of muscle proteins, which can help treat conditions such as heart failure, amyotrophic lateral sclerosis (ALS), and other muscle disorders. Cytokinetics focuses on providing new treatment options for patients for whom current therapies are insufficiently effective.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.